Skip to main content
Elsevier

Oral Delivery of Therapeutic Peptides and Proteins

  • 1st Edition - August 18, 2022
  • Latest edition
  • Editors: Puneet Tyagi, Anand Subramony
  • Language: English

Oral Delivery of Therapeutic Peptides and Proteins provides a complete overview of the journey scientists pursue to attain protein and peptide oral delivery. The book highlight… Read more

Description

Oral Delivery of Therapeutic Peptides and Proteins provides a complete overview of the journey scientists pursue to attain protein and peptide oral delivery. The book highlights the physiological challenges that must be accounted for in addition to overcoming protease inhibition and acid stability issues that are commonly mentioned in this area of research. Primary topics include formulation technologies being adopted for oral delivery of proteins and peptides, modification of actives to make them more suited for oral delivery, animal models and their shortcomings in assessing oral bioavailability, and in vitro models to simulate drug absorption and transport.

Academics and industry researchers working in formulation development and researchers and advanced students in biotechnology and pharmacy will find this a useful resource.

Key features

  • Demonstrates how proteins and peptides transport throughout the gastrointestinal tract and how to evaluate their biological fate when encapsulated into certain delivery systems
  • Examines developing technologies to improve future oral bioavailability
  • Includes the in vitro and preclinical techniques needed for development

Readership

Academics and industry researchers working in formulation development. Researchers and advanced students in biotechnology and pharmacy

Table of contents

1. Formulation technologies being adopted for oral delivery of proteins and peptides

2. Modification of actives to make them more suited for oral delivery

3. Animal models and their shortcomings in assessing oral bioavailability

4. In vitro models to simulate drug absorption and transport

5. Futuristic technologies to improve oral bioavailability

Product details

  • Edition: 1
  • Latest edition
  • Published: August 18, 2022
  • Language: English

About the editors

PT

Puneet Tyagi

Puneet Tyagi is an Associate Director with the Dosage Form Design and Development group at AstraZeneca, based in Maryland, USA. Puneet leads a team of scientists in the area of biologics formulation development, with a focus on long acting formulations, transdermal delivery, and oral delivery of biologics. Puneet received his bachelor’s and master’s degrees in pharmaceutical sciences from India and his PhD from the University of Colorado. Puneet Tyagi is co-inventor of several U.S. and international patents and has published extensively in the field of drug delivery.
Affiliations and expertise
Associate Director, Dosage Form Design and Development, AstraZeneca

AS

Anand Subramony

Anand Subramony is Vice President within the Biologics Engineering group, R&D, at AstraZeneca (AZ) and leads various cross-functional programs and teams in drug delivery and nanomedicine (for targeted delivery, enabling new modalities for genomic medicine, and creating technology platforms). In addition, he provides leadership to AZ’s external innovation initiatives and CoSolve, an AZ open innovation platform that brings compelling technologies to the portfolio. Before serving in his current role, Dr. Subramony headed the Drug Delivery & Device Development group at MedImmune and built an internal team that focused on combination product development for biologics and oral peptide delivery and other novel controlled release technologies for Biologics. One of the early pioneers in digital health technology solutions in pharma, Dr. Subramony led several novel connected health initiatives in the pharma value chain including remote patient monitoring, adaptive therapy, and continuous monitoring with diagnostic sensors, wearables and use of smartphone Apps. In prior roles, he was Principal Fellow and Head of Novel Delivery Technologies at the Novartis Institutes for BioMedical Research (NIBR, Cambridge, MA), Head of the Materials Science group (E-TRANS) at J&J (Alza, Mountain View, CA), and Director of Materials Science & Drug delivery at Dr. Reddy’s Laboratories (Bridgewater, NJ). With his broad experience in pharma biotech, Dr. Subramony brings innovation, scientific rigor, and execution excellence, with a sense of urgency toward drug development to create patient-centric products. Dr. Subramony holds an M.S. degree in Materials Science Engineering (IIT, Bombay) and a Ph.D. degree from Purdue University and was a research scientist at the University of Washington, Seattle. With several refereed publications and patents, he is a Key Opinion Leader for bringing innovations through drug delivery, devices, and digital health.
Affiliations and expertise
Vice President, R&D, AstraZeneca

View book on ScienceDirect

Read Oral Delivery of Therapeutic Peptides and Proteins on ScienceDirect